Current Price Status
Stock is in Momentum
Stock is currently overvalued by the market with the expectation of annual earning growth at 36.78% to match current price.
Overvalued stock can be traded very volatile. If the earning growth momentum continue, overvalued stock can match into fair value, on the flip side, the downside risk can be huge if the stock is not meeting the market expectation.
Company is in Positive Earning
- TOPVISN current price is 9.56% above OneDelta estimated fair value.
The fair value is estimated via OneDelta proprietary model that updated daily basis based on stock fundamental and specific industry relative marco outlook. It can be assessed as stock potential upside range or the stock true value price in case of downside.
Bank Analyst Price Targets
Revenue & Earning Growth Analysis
Potential Better Revenue Growth
TOPVISN posted a better revenue growth than average in the recent quarter.
Recent Positive Profit Growth
TOPVISN managed to achieve better profit growth on the past 2 quarters by average +65%.
Past Quarter Reports
|Quarter Date||Revenue (RM)||(%)||EPS (RM)||(%)|
Volume Trend Analysis
Recent Volume is Decreasing
Decreasing trading volume tends to keep stock price range bound in near term.
Low Volume/Liquidity Stock
Only RM0k worth of stock was traded for this stock past month. Low liquidity stock is danger for price manipulation and more difficult to sell at market price.
TOPVISN recent daily traded volume is NAN% lower than past month average.
|Past 30-Day||Past 5-Day|
|0k daily||0k daily|
Price History Chart
Past 30-day Average Price: RM0.75
Stock Fundamental Factors
Fundamental factor characteristics help us understand and expect how the stock price will behave in short and long term.
Stocks that have little trading volume on usual market time
Stock Thematic Baskets
Usually the more the stock is included in popular themes, the more opportunity for price-driven momentum and better liquidity.
Stock Company Profile
TOPVISION EYE SPECIALIST BERHAD
TOPVISION Eye Specialist Bhd. is an investment holding company, which engages in the provision of ophthalmology services and related medical consultancy. It specializes in the fields of cataract and retina surgery, glaucoma filtering surgery, corneal and external eye diseases, oculoplastic surgery, pterygium excision with conjunctival autograft, paediatric ophthalmology, and ophthalmologists. The company was founded by Hock Nean Liew in 2010 and is headquartered in Shah Alam, Malaysia.